While 2022 has been devastating for cannabis stocks amid lackluster prospects for federal legalization, debt prices in some larger U.S. cannabis companies have fared relatively well, market observers said. Curaleaf Read more
While 2022 has been devastating for cannabis stocks amid lackluster prospects for federal legalization, debt prices in some larger U.S. cannabis companies have fared relatively well, market observers said. Curaleaf Read more